Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study
Gordon J, Cox M, De Placido P, Ribera D, Omlin A, Buonocore G, Chi K, Kollmannsberger C, Khalaf D, Facchini G, Sonpavde G, De Placido S, Eigl B, Cherhroudi C, Pignata S, Battaglia M, Buonerba C, Pond G, Crona D, Gillessen Sommer S, Lucarelli G, Rossetti S, Dorff T, Artale S, Locke J, Bosso D, Milowsky M, Witek M, Di Lorenzo G. Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study. Oncotarget 2018; 9:19861-19873.
13.04.2018
Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study
13.04.2018
Oncotarget 2018; 9:19861-19873
Gordon Jacob A, Cox Michael E, De Placido Pietro, Ribera Dario, Omlin Aurelius, Buonocore Gaetano, Chi Kim, Kollmannsberger Christian, Khalaf Daniel, Facchini Gaetano, Sonpavde Guru, De Placido Sabino, Eigl Bernhard J, Cherhroudi Cyrus, Pignata Sandro, Battaglia Michele, Buonerba Carlo, Pond Gregory, Crona Daniel, Gillessen Sommer Silke, Lucarelli Giuseppe, Rossetti Sabrina, Dorff Tanya, Artale Salvatore, Locke Jennifer A, Bosso Davide, Milowsky Matthew Ivan, Witek Mira Sofie, Di Lorenzo Giuseppe
Weiter
